Scarica l'app Stockscreener
1.13
3.42%
-0.04
Pre-mercato:
1.10
-0.03
-2.65%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CHRS Giù?
Forum
Previsione
Coherus Oncology Inc Borsa (CHRS) Ultime notizie
Coherus Oncology: On The Shaping Up (NASDAQ:CHRS) - Seeking Alpha
Penny Stocks to Watch: Lantronix and Coherus Oncology Among Top Picks - AInvest
Lobbying Update: $125,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed - Quiver Quantitative
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q2 2025 Earnings Call Transcript - Insider Monkey
Coherus Oncology’s Earnings Call Highlights Growth and Challenges - TipRanks
Analysts' Revenue Estimates For Coherus Oncology, Inc. (NASDAQ:CHRS) Are Surging Higher - 富途牛牛
Coherus Oncology's (CHRS) Strategic Reinvention: A High-Conviction Biotech Play for the Long Term - AInvest
Industry Analysts Just Upgraded Their Coherus Oncology, Inc. (NASDAQ:CHRS) Revenue Forecasts By 21% - simplywall.st
Need To Know: Analysts Are Much More Bullish On Coherus Oncology, Inc. (NASDAQ:CHRS) Revenues - Yahoo Finance
Coherus Oncology 2025 Q2 Earnings Strong Turnaround with 2404.5% Net Income Surge - AInvest
Coherus Oncology shares rise 4.07% premarket after Q2 revenue up 36%. - AInvest
Earnings call transcript: Coherus BioSciences Q2 2025 misses EPS, stock dips - Investing.com
Earnings call transcript: Coherus BioSciences Q2 2025 misses EPS, stock dips By Investing.com - Investing.com South Africa
Coherus Oncology Inc (CHRS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Coherus Oncology Inc (CHRS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Coherus (CHRS) Q2 Revenue Jumps 10% - AOL.com
Coherus Oncology Reports Strong Q2 2025 Growth - TipRanks
Coherus Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 - 富途牛牛
Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Coherus Oncology: Q2 Earnings Snapshot - San Antonio Express-News
Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Coherus Oncology Q2 2025: LOQTORZI revenue up 36% to $10.0mln. - AInvest
Coherus Oncology Reports Second Quarter 2025 Financial Results a - GuruFocus
Coherus Oncology Reports 36% Increase in LOQTORZI Net Revenue for Q2 2025 and Updates on Pipeline Progress - Quiver Quantitative
Insights Ahead: Coherus BioSciences's Quarterly Earnings - 富途牛牛
Coherus Oncology, Inc. (NASDAQ:CHRS) is largely controlled by institutional shareholders who own 54% of the company - Yahoo Finance
Coherus Oncology Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
What is Coherus BioSciences Inc. company’s growth strategyLightning-fast capital gains - Jammu Links News
Earnings Preview: CHRS to Report Financial Results Post-market on August 07 - 富途牛牛
Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 | CHRS Stock News - GuruFocus
Coherus Oncology to Release Second Quarter 2025 Financial Results on August 7, 2025 - Quiver Quantitative
Coherus Earnings: Q2 2025 Results and Management Call Set for August 7 After Market Close - Stock Titan
Why Coherus BioSciences Inc. stock attracts strong analyst attentionHigh Reward Risk Balanced Trading - metal.it
Coherus Oncology, Inc.'s (NASDAQ:CHRS) Price Is Right But Growth Is Lacking After Shares Rocket 35% - simplywall.st
Positive week for Coherus Oncology, Inc. (NASDAQ:CHRS) institutional investors who lost 47% over the past year - simplywall.st
Alvotech: A Fast Expanding Biosimilar Concern (NASDAQ:ALVO) - Seeking Alpha
Coherus BioSciences, Inc. (NASDAQ:CHRS) Analysts Are Reducing Their Forecasts For This Year - 富途牛牛
Coherus Biosciences Receives Nasdaq Deficiency Notice - TipRanks
Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength? - Yahoo Finance
Coherus Oncology reports annual meeting results By Investing.com - Investing.com Canada
Coherus Oncology reports annual meeting results - Investing.com
Coherus Biosciences Holds Virtual Annual Stockholder Meeting - TipRanks
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory - Insider Monkey
Coherus Oncology shares fall 1.20% after-hours following resignation of Chief Commercial Officer. - AInvest
Coherus at Jefferies Conference: Strategic Growth and Pipeline Focus - Investing.com
Coherus at Jefferies Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada
Coherus BioSciences Renames to Coherus Oncology, Focusing on Cancer Treatments. - AInvest
Genocea Biosciences (NASDAQ:GNCAQ) vs. Coherus BioSciences (NASDAQ:CHRS) Critical Survey - Defense World
Coherus Oncology (CHRS) Shifts Focus with New Name and Innovativ - GuruFocus
0.95%
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):